Pharmaceutical formulations comprising a pyridylaminoacetic acid compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE48183
SERIAL NO

16114721

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANTEN PHARMACEUTICAL CO LTDHIGASHIYODOGAWA-KU OSAKA-SHI OSAKA 533-8651

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kawabata, Noriko Osaka, JP 12 34
Kawata, Hisashi Osaka, JP 10 34
Kroon, Henk-Andre Emeryville, US 13 58
Shams, Naveed Emeryville, US 16 1259

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 1, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 1, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00